US2021340190A1PendingUtilityA1

Flagellin compositions and uses

77
Assignee: GENOME PROT INCPriority: Jul 30, 2014Filed: May 13, 2021Published: Nov 4, 2021
Est. expiryJul 30, 2034(~8 yrs left)· nominal 20-yr term from priority
Inventors:Vadim Mett
A61K 38/164A61K 2039/57A61P 9/10A61K 2039/55594A61K 2039/55516A61K 39/39A61K 2039/55583Y02A50/30A61P 37/08A61K 2039/55505A61P 37/02A61P 35/02A61K 45/06C07K 14/195A61P 37/04A61P 35/00A61P 31/04A61P 31/20A61P 31/16C07K 2319/00A61P 31/12A61K 2039/575A61K 39/0013A61P 43/00C07K 2319/21A61K 39/02
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.

Claims

exact text as granted — not AI-modified
1 - 60 . (canceled) 
     
     
         61 . A composition comprising a polypeptide having an amino acid sequence that is about 95% identical to SEQ ID NO: 137. 
     
     
         62 . The composition of  claim 61 , the composition comprising a polypeptide having an amino acid sequence that is about 98% sequence identical to SEQ ID NO: 137. 
     
     
         63 . The composition of  claim 61 , the composition comprising a polypeptide having an amino acid sequence that is about 99% sequence identical to SEQ ID NO: 137. 
     
     
         64 . The composition of  claim 61 , the composition comprising a polypeptide having an amino acid sequence that is SEQ ID NO: 137. 
     
     
         65 . A pharmaceutical composition, the pharmaceutical composition comprising a polypeptide having the amino acid sequence of SEQ ID NO: 137, and a pharmaceutically acceptable carrier. 
     
     
         66 . The composition of  claim 61 , wherein the composition has reduced antigenicity and immunogenicity as compared to the polypeptide SEQ ID NO: 2. 
     
     
         67 . The composition of  claim 61 , wherein the composition demonstrates improved pharmacokinetics as compared to the polypeptide SEQ ID NO: 2. 
     
     
         68 . The composition of  claim 61 , wherein the composition activates TLR5 signaling at a level the same as, or similar to, that of the polypeptide SEQ ID NO: 2. 
     
     
         69 . The composition of  claim 61 , wherein the polypeptide further comprises a N-terminal tag. 
     
     
         70 . The composition of  claim 61 , wherein the polypeptide further comprises a C-terminal tag. 
     
     
         71 . The composition of  claim 61 , wherein the composition induces NF-κB mediated expression of one or more of the cytokines selected from IL-6, IL-12, keratinocyte chemoattractant (KC), IL-10, G-CSF, MCP-1, TNF-α, MIG, and MIP-2. 
     
     
         72 . A pharmaceutical composition comprising the composition of  claim 61  and a pharmaceutically acceptable carrier. 
     
     
         73 . A method of stimulating TLR5 signaling comprising administering to a subject in need thereof a composition comprising a polypeptide having an amino acid sequence that is about 95% sequence identical to SEQ ID NO: 137. 
     
     
         74 . The method of  claim 73 , wherein the subject suffers from radiation-induced cellular damage. 
     
     
         75 . The method of  claim 73 , wherein the subject has been subjected to a lethal dose of radiation. 
     
     
         76 . The method of  claim 73 , wherein the subject is undergoing radiation treatment. 
     
     
         77 . The method of  claim 73 , wherein the composition has reduced antigenicity and immunogenicity as compared to the polypeptide SEQ ID NO: 2.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.